00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
17:58 , Nov 9, 2018 |  BC Week In Review  |  Company News

Illumina taking out Pacific Biosciences for $1.2B

Illumina Inc. (NASDAQ:ILMN) is acquiring fellow genomics company Pacific Biosciences of California Inc. (NASDAQ:PACB) for $8 per share in cash, or about $1.2 billion. The price is a 77% premium to Pacific Biosciences' close of...
22:47 , Nov 1, 2018 |  BC Extra  |  Company News

Illumina taking out Pacific Biosciences for $1.2B

Illumina Inc. (NASDAQ:ILMN) is acquiring fellow genomics company Pacific Biosciences of California (NASDAQ:PACB) for $8 per share in cash, or about $1.2 billion. The price is a 77% premium to Pacific Biosciences' close of $4.51...
13:06 , Sep 14, 2018 |  BC Week In Review  |  Financial News

Pacific Biosciences prices $60M follow-on

Genomics company Pacific Biosciences of California (NASDAQ:PACB) priced a $60 million follow-on on Sept. 12 through the sale of 14.2 million shares at $4.25 underwritten by Cowen and Cantor Fitzgerald. The price is a 4%...
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
20:24 , Feb 23, 2018 |  BC Week In Review  |  Financial News

Pacific raises $30M in follow-on

Sequencing company Pacific Biosciences of California Inc. (NASDAQ:PACB) raised $30 million on Feb. 13 through the sale of 12.5 million shares at $2.40 in a follow-on underwritten by Cantor. The price is a 6% discount...
22:53 , Nov 3, 2017 |  BC Extra  |  Company News

Management tracks: Tissue Regenix, Therapix

Regenerative medical device company Tissue Regenix Group plc (LSE:TRX) named Steve Couldwell CEO. A Tissue Regenix director since 2013, Couldwell was COO of global biosurgery at Sanofi (Euronext:SAN; NYSE:SNY). Cannabinoid company Therapix Biosciences Ltd. (Tel...
21:36 , Dec 16, 2016 |  BC Week In Review  |  Company News

Pacific Biosciences, Roche deal

Roche said it will terminate a 2013 deal to develop and commercialize diagnostics based on Pacific’s Single Molecule Real-Time (SMRT) technology. Roche will have no rights to the technology except for non-exclusive rights to products...
00:00 , Dec 16, 2016 |  BC Extra  |  Company News

Roche ending diagnostics deal with Pacific Biosciences

Pacific Biosciences of California Inc. (NASDAQ:PACB) dropped $3.01 (44%) to $3.89 on Thursday after it said Roche (SIX:ROG; OTCQX:RHHBY) plans to terminate a 2013 deal to develop and commercialize diagnostics based on Pacific’s Single Molecule...
07:00 , Apr 7, 2016 |  BC Innovations  |  Tools & Techniques

Sexy sequencing

Tim Harris, Venture Partner, SV Life Sciences  The days when PhDs were minted based on sequencing a few nucleotides at the end of a piece of nucleic acid are definitely gone. The countless hours spent...